{"id":"W4281715825","doi":"10.1200/jco.2022.40.16_suppl.11523","title":"Results of a phase I dose escalation and expansion study of tegavivint (BC2059), a first-in-class TBL1 inhibitor for patients with progressive, unresectable desmoid tumor.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Soft tissue tumor case studies","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Iterion Therapeutics","keywords":"Medicine; Internal medicine; Maximum tolerated dose; Adverse effect; Nuclear medicine; Gastroenterology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002695652,0.000147482,0.001576745,0.0002497268,0.0000824488,0.000003083115,0.0000990769,0.00007633948,0.00001834814],"category_scores_gemma":[0.00657064,0.0001025267,0.000142172,0.0003197844,0.0002087163,0.00009545691,0.0001484368,0.0005799757,1.559466e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001655291,"about_ca_system_score_gemma":0.0005789858,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004035637,"about_ca_topic_score_gemma":0.0001664824,"domain_scores_codex":[0.9958189,0.0004221358,0.002689217,0.0002528959,0.0006096599,0.0002072474],"domain_scores_gemma":[0.9927331,0.003154681,0.002953321,0.0001872065,0.0008104332,0.0001612285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1745095,0.0508678,0.7418324,0.0002267921,0.0004567218,0.00100809,0.003110248,0.000117753,0.0002380048,0.000006211603,0.001237277,0.02638919],"study_design_scores_gemma":[0.1337846,0.2696514,0.588376,0.0003277482,0.0005129577,0.0001401951,0.004358864,0.0002972645,0.0001443531,0.0000506444,0.002241433,0.0001145614],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970732,0.0002769929,0.000006889356,0.0006637952,0.0003463104,0.001531748,0.00002937311,0.000005415629,0.00006626801],"genre_scores_gemma":[0.9983461,0.00002280798,0.001264147,0.00006870565,0.0001723943,0.00007394952,0.000006539451,0.00001891897,0.00002644236],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2187836,"threshold_uncertainty_score":0.7866145,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07077747817959736,"score_gpt":0.4341381408203555,"score_spread":0.3633606626407581,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}